Korea United Pharmaceutical enters Myanmar market for osteoporosis treatment

At the signing ceremony for the supply contract for osteoporosis treatment ‘Bondex Injection’, dr. CEO Htin Paw (right) and Korea United Pharmaceutical Managing Director Yang Jin-young (left) are taking a commemorative photo.

(Health Korea News / Lee Si-woo) United Pharmaceutical Korea (CEO Deok-young Kang) signed an export contract for its osteoporosis treatment with Myanmar’s United MCK (CEO Dr. Htin Paw), further strengthening its position in the Southeast Asian market.

Korea United Pharmaceutical is a company that is carrying out various global businesses such as export voucher business and overseas branching business with KOTRA (Korea Trade-Investment Promotion Agency), and signed a contract by attending the GBPP (Global Bio & Pharma Plaza) 2024 event held for two days from the 22nd to the 23rd. A signing ceremony was held.

At this event, United Pharmaceutical Korea signed a supply contract with United MCK, a Myanmar pharmaceutical company, for the osteoporosis treatment Bondex Injection (ingredient name: Ibandronate), laying the foundation for continued export of medicines to Myanmar, which has recently suffered political and economic difficulties. prepared.

United MCK is a subsidiary of Sakura Hospital Group, which operates three hospitals in Myanmar, and has an advantage in establishing a presence in the market as it can stably supply its medicines through its own hospitals.

Yang Jin-young, managing director of United Pharmaceutical Korea, who attended the contract signing ceremony, said, “This contract with Myanmar United MCK is an example of our company’s competitiveness and product excellence in the Southeast Asian pharmaceutical market,” and added, “We plan to actively pursue exports of additional pharmaceuticals, including contrast media.” .

For reference, GBPP is Korea’s largest pharmaceutical export consultation event held by the Ministry of Trade, Industry and Energy together with KOTRA and the Korea Pharmaceutical Import and Export Association to support exports of domestic pharmaceutical and bio companies. At this event, 150 domestic companies and about 100 overseas buyers attended and had the opportunity to expand exports and partnerships.

Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited

Source: www.hkn24.com